Expansion of the Medicare drug price negotiation rare disease drug carve-out would unnecessarily limit the number of drugs ...

US insurance giant Cigna has taken fresh legal action against Bristol Myers Squibb (NYSE: BMY), accusing the drugmaker of ...

Surbhi Sidana, MD, discusses updates from the CARTITUDE-4 study assessing the CAR T therapy cilta-cel in patients with ...

Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse ...

Long-term CARTITUDE-1 data show ciltacabtagene autoleucel (cilta-cel) may offer lasting remission and survival in relapsed/refractory multiple myeloma, according to Sundar Jagannath, MBBS, of the ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...

Cigna (NYSE:CI) on Tuesday filed an antitrust lawsuit accusing Bristol Myers Squibb (NYSE:BMY) of breaching U.S. competition ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...

Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard ...

The phase 3 IRAKLIA trial assesses subcutaneous isatuximab via on-body injector vs intravenous (IV) administration, in combination with pomalidomide and dexamethasone, in relapsed/refractory multiple ...

We conducted a multicohort, open-label, phase 1/2 trial (CC-220-MM-001) at 42 treatment centres in Europe, Canada, and the USA. Patients aged 18 years or older with multiple myeloma who had received ...

CARTITUDE-4 is a Phase 3 study evaluating CARVYKTI ® versus two standard of care (SOC) therapies of pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, dexamethasone (DPd) ...